154 related articles for article (PubMed ID: 27480274)
1. RANK Signaling Blockade Reduces Breast Cancer Recurrence by Inducing Tumor Cell Differentiation.
Yoldi G; Pellegrini P; Trinidad EM; Cordero A; Gomez-Miragaya J; Serra-Musach J; Dougall WC; Muñoz P; Pujana MA; Planelles L; González-Suárez E
Cancer Res; 2016 Oct; 76(19):5857-5869. PubMed ID: 27480274
[TBL] [Abstract][Full Text] [Related]
2. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.
Gonzalez-Suarez E; Jacob AP; Jones J; Miller R; Roudier-Meyer MP; Erwert R; Pinkas J; Branstetter D; Dougall WC
Nature; 2010 Nov; 468(7320):103-7. PubMed ID: 20881963
[TBL] [Abstract][Full Text] [Related]
3. RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment.
van Dam PA; Verhoeven Y; Trinh XB; Wouters A; Lardon F; Prenen H; Smits E; Baldewijns M; Lammens M
Crit Rev Oncol Hematol; 2019 Jan; 133():85-91. PubMed ID: 30661662
[TBL] [Abstract][Full Text] [Related]
4. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling.
Tan W; Zhang W; Strasner A; Grivennikov S; Cheng JQ; Hoffman RM; Karin M
Nature; 2011 Feb; 470(7335):548-53. PubMed ID: 21326202
[TBL] [Abstract][Full Text] [Related]
5. RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.
Palafox M; Ferrer I; Pellegrini P; Vila S; Hernandez-Ortega S; Urruticoechea A; Climent F; Soler MT; Muñoz P; Viñals F; Tometsko M; Branstetter D; Dougall WC; González-Suárez E
Cancer Res; 2012 Jun; 72(11):2879-88. PubMed ID: 22496457
[TBL] [Abstract][Full Text] [Related]
6. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
[TBL] [Abstract][Full Text] [Related]
7. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
8. RANKL inhibition: a promising novel strategy for breast cancer treatment.
González-Suárez E
Clin Transl Oncol; 2011 Apr; 13(4):222-8. PubMed ID: 21493182
[TBL] [Abstract][Full Text] [Related]
9. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
10. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
[TBL] [Abstract][Full Text] [Related]
11. RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini.
Gonzalez-Suarez E; Branstetter D; Armstrong A; Dinh H; Blumberg H; Dougall WC
Mol Cell Biol; 2007 Feb; 27(4):1442-54. PubMed ID: 17145767
[TBL] [Abstract][Full Text] [Related]
12. RANK links senescence to stemness in the mammary epithelia, delaying tumor onset but increasing tumor aggressiveness.
Benítez S; Cordero A; Santamaría PG; Redondo-Pedraza J; Rocha AS; Collado-Solé A; Jimenez M; Sanz-Moreno A; Yoldi G; Santos JC; De Benedictis I; Gómez-Aleza C; Da Silva-Álvarez S; Troulé K; Gómez-López G; Alcazar N; Palmero I; Collado M; Serrano M; Gonzalez-Suarez E
Dev Cell; 2021 Jun; 56(12):1727-1741.e7. PubMed ID: 34004159
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
Dougall WC
Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
[TBL] [Abstract][Full Text] [Related]
14. Receptor activator for nuclear factor-κB ligand signaling promotes progesterone-mediated estrogen-induced mammary carcinogenesis.
Boopalan T; Arumugam A; Parada J; Saltzstein E; Lakshmanaswamy R
Cancer Sci; 2015 Jan; 106(1):25-33. PubMed ID: 25412610
[TBL] [Abstract][Full Text] [Related]
15. [Control of bone resorption by RANKL-RANK system].
Harada S; Takahashi N
Clin Calcium; 2011 Aug; 21(8):1121-30. PubMed ID: 21814016
[TBL] [Abstract][Full Text] [Related]
16. RANKL and RANK: From Mammalian Physiology to Cancer Treatment.
Rao S; Cronin SJF; Sigl V; Penninger JM
Trends Cell Biol; 2018 Mar; 28(3):213-223. PubMed ID: 29241686
[TBL] [Abstract][Full Text] [Related]
17. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
18. Receptor activator of nuclear factor-kappa B ligand (RANKL) stimulates bone-associated tumors through functional RANK expressed on bone-associated cancer cells?
Mori K; Ando K; Heymann D; Rédini F
Histol Histopathol; 2009 Feb; 24(2):235-42. PubMed ID: 19085839
[TBL] [Abstract][Full Text] [Related]
19. RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy.
Azim HA; Peccatori FA; Brohée S; Branstetter D; Loi S; Viale G; Piccart M; Dougall WC; Pruneri G; Sotiriou C
Breast Cancer Res; 2015 Feb; 17():24. PubMed ID: 25849336
[TBL] [Abstract][Full Text] [Related]
20. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
Nolan E; Vaillant F; Branstetter D; Pal B; Giner G; Whitehead L; Lok SW; Mann GB; ; Rohrbach K; Huang LY; Soriano R; Smyth GK; Dougall WC; Visvader JE; Lindeman GJ
Nat Med; 2016 Aug; 22(8):933-9. PubMed ID: 27322743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
